Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

AVM Biotechnology

Status

Conditions: Breast Cancer; Hodgkin Lymphoma; Glioblastoma; Squamous Cell Carcinoma; Non-hodgkin Lymphoma; Cancer; Ovarian Cancer; Esophageal Andeocarcinoma; Tumor, Brain; Tumor, Solid; Acute Leukemia; Gastric Cancer; Desmoplastic Round Cell Sarcoma; Mixed Phenotype AML; Spindle Cell Sarcoma; Prostate Cancer; Pancreatic Cancer

Treatments: Drug: Proton pump inhibitor; Drug: AVM0703; Drug: Hydrocortisone

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT05974410

AVM0703-EAP

Details and patient eligibility

About

AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO. As of July 2024, 37 patients have been treated through this FDA-EAP including patients diagnosed with relapsed or recurring glioblastoma, inoperable/chemotherapy ineligible CNS Squamous Cell Carcinoma, metastatic Breast Cancer, ovarian cancer, gastric cancer, Hodgkin's Lymphoma, Mixed Phenotype Acute Myelogenous Leukemia, colon cancer, B-ALL, Malignant Myxoid Spindle Cell Neoplasm, non-small cell lung cancer, DLBCL with CNS involvement, metastatic prostate cancer, Anaplastic T-cell Non-Hodgkin's Lymphoma and metastatic pancreatic cancer. Drug-related side-effects are predominantly grade 1 and include itching during the infusion and about 1 week of low grade insomnia.

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

-

Exclusion criteria

-